Cargando…

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

PURPOSE: Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Daniel, Zheng, Yun, Tyner, Jeffrey W., Chng, Wee Joo, Chien, Wen Wen, Gery, Sigal, Leong, Geraldine, Braunstein, Glenn D., Koeffler, H. Phillip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742422/ https://www.ncbi.nlm.nih.gov/pubmed/23824064 http://dx.doi.org/10.1007/s00432-013-1465-6

Ejemplares similares

Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling
por: Valiuliene, Giedre, et al.
Publicado: (2015)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer
por: Helland, Øystein, et al.
Publicado: (2016)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
por: Kong, Li R., et al.
Publicado: (2017)

Repurposing Belinostat for Alleviation of Atopic Dermatitis
por: Quah, Shan, et al.
Publicado: (2021)

HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013)

Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells
por: Gnedina, Olga O., et al.
Publicado: (2023)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
por: Allen, Pamela B, et al.
Publicado: (2018)

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
por: Chien, Wenwen, et al.
Publicado: (2023)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

The Role of HDACs and HDACi in Cartilage and Osteoarthritis
por: Zhang, He, et al.
Publicado: (2020)

CLU blocks HDACI-mediated killing of neuroblastoma
por: Subramanian, Chitra, et al.
Publicado: (2010)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
por: Buckley, Michael T, et al.
Publicado: (2007)

Monitoring the effect of belinostat in solid tumors by H4 acetylation
por: MARQUARD, LENA, et al.
Publicado: (2008)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014)

New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
por: Reimer, Peter
Publicado: (2015)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cells in vivo and in vitro
por: Bai, Miao, et al.
Publicado: (2021)

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
por: Dovzhanskiy, Dmitriy I, et al.
Publicado: (2012)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Preclinical efficacy of belinostat in combination with zidovudine in adult T-cell leukemia-lymphoma
por: Toomey, Ngoc, et al.
Publicado: (2015)

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
por: Lim, Su Lin, et al.
Publicado: (2019)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Vimentin, colon cancer progression and resistance to butyrate and other HDACis
por: Lazarova, Darina L., et al.
Publicado: (2016)

The Promising Role of New Generation HDACis in Anti-Cancer Therapies
por: Hervouet, Eric
Publicado: (2018)

Teratoma Growth Retardation by HDACi Treatment of the Tumor Embryonal Source
por: Krasic, Jure, et al.
Publicado: (2020)

HDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
por: Squarzoni, Angelica, et al.
Publicado: (2022)

Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model
por: Kaczmarek, Jessica V., et al.
Publicado: (2021)

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
por: Takebe, Naoko, et al.
Publicado: (2019)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
por: Wang, Ling-Zhi, et al.
Publicado: (2013)

Panobinostat for the treatment of multiple myeloma: the evidence to date
por: Bailey, Hanna, et al.
Publicado: (2015)

HDACi and Nrf2: not from alpha to omega but from acetylation to OA
por: Jahr, Holger
Publicado: (2015)

Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
por: Bayat Mokhtari, Reza, et al.
Publicado: (2017)

Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2021)

The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death
por: Hsu, Kai-Wen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7bc2brvoqa01r1f9hr78ek11sc